Director Milligan Sandra bought 26,050 shares of GOSS at $1.92, 81.4% increase in holdings, as stock rises 68.1% over 90 days from unprofitable biotech.
Director Milligan Sandra acquired 26,050 shares at $1.92 on 2025-08-19, expanding her stake by 81.4% from 32,000 to 58,050 shares for a total of $50,016.00. This accumulation is materially sized and follows a prior buy at this ticker on 2023-11-15 that returned +20.2% over 90 days. The timing is notable: the stock has appreciated 68.1% over the past 90 days and currently trades at $1.95, within 10.1% of its 52-week high. However, the company remains unprofitable with a net loss of $38,273,000.00 against quarterly revenue of $11,489,000.00, placing the transaction in a financially distressed biotech context where price momentum may not align with underlying business performance. The director's prior transaction at this ticker showed favorable 90-day returns, establishing a pattern of well-timed entry points, though the current fundamental picture—significant operating losses—warrants scrutiny of whether the recent stock appreciation reflects technical momentum or improved business prospects.